Ocifisertib
Based on 9 publication(s) in Google Scholar
CFI-400945 free base is a potent, selective and orally bioavailable PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM, respectively.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.78%
- CAS No.: 1338806-73-7
- 화학식: C33H34N4O3
- 분자량:534.65
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
HY-50877
GSK461364PLK1 Inhibitor -
HY-18682
CentrinonePLK4 Inhibitor -
HY-15828
OnvansertibPLK1 Inhibitor -
HY-12137
VolasertibPLK1 Inhibitor -
HY-50698
BI 2536PLK1 Inhibitor -
HY-15161
Ro3280PLK1 Inhibitor -
HY-10971
AlisertibAurora A Kinase Inhibitor -
HY-18683
Centrinone-BPLK4 Inhibitor -
HY-10127
BarasertibAurora B Inhibitor -
HY-100789
ON1231320PLK2 Inhibitor -
HY-12037A
RigosertibPI3K Inhibitor -
HY-15160
TAK-960PLK1 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Ocifisertib
More- Nat Nanotechnol. 2021 Jul;16(7):830-839. [Abstract]
- Cell Death Differ. 2026 May 25. [Abstract]
- J Integr Plant Biol. 2026 Apr 2. [Abstract]
- Cell Chem Biol. 2026 Aug 20;33(8):1117-1134.e6.
- Int J Mol Med. 2021 Jan;47(1):151-160. [Abstract]
- Cancer Cell Int. 2026 Jun 18.
- Mol Cancer Ther. 2026 Jul 15:10.1158/1535-7163.MCT-26-0182.
- J Cancer Res Clin Oncol. 2020 Nov;146(11):2871-2883. [Abstract]
- Ir J Med Sci. 2023 Apr;192(2):561-567. [Abstract]
Customer Validation & Images
-
WB
-
WB
-
Cell Imaging/Staining
-
WB
-
WB
Biological Activity
제품 설명
IC50 & Target
[1]|
PLK4 2.8 nM (IC50) |
AURKA 140 nM (IC50) |
AURKB/INCENP 98 nM (IC50) |
TIE2/TEK 22 nM (IC50) |
TRKA 6 nM (IC50) |
TRKB 9 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | GI50 |
0.005 μM
Compound: 48
|
Growth inhibition of human A549 cells after 5 days by SRB assay
Growth inhibition of human A549 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| BT-20 | GI50 |
0.058 μM
Compound: 48
|
Growth inhibition of human BT20 cells after 5 days by SRB assay
Growth inhibition of human BT20 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| CAL-51 | GI50 |
0.26 μM
Compound: 48
|
Growth inhibition of human CAL51 cells after 5 days by SRB assay
Growth inhibition of human CAL51 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| COLO 205 | GI50 |
0.017 μM
Compound: 48
|
Growth inhibition of human COLO205 cells after 5 days by SRB assay
Growth inhibition of human COLO205 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| HCC1954 | GI50 |
0.005 μM
Compound: 48
|
Growth inhibition of human HCC1954 cells after 5 days by SRB assay
Growth inhibition of human HCC1954 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| HCT-116 | GI50 |
0.004 μM
Compound: 48
|
Growth inhibition of human HCT116 cells after 5 days by SRB assay
Growth inhibition of human HCT116 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| HMEC | GI50 |
9 μM
Compound: 48
|
Growth inhibition of human HMEC cells after 5 days by SRB assay
Growth inhibition of human HMEC cells after 5 days by SRB assay
|
[PMID: 25723005] |
| MCF7 | GI50 |
0.008 μM
Compound: 48
|
Growth inhibition of human MCF7 cells after 5 days by SRB assay
Growth inhibition of human MCF7 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| MDA-MB-231 | GI50 |
8.6 μM
Compound: 48
|
Growth inhibition of human MDA-MB-231 cells after 5 days by SRB assay
Growth inhibition of human MDA-MB-231 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| MDA-MB-468 | GI50 |
0.006 μM
Compound: 48
|
Growth inhibition of human MDA-MB-468 cells after 5 days by SRB assay
Growth inhibition of human MDA-MB-468 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| OVCAR-3 | GI50 |
0.018 μM
Compound: 48
|
Growth inhibition of human OVCAR3 cells after 5 days by SRB assay
Growth inhibition of human OVCAR3 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| SK-BR-3 | GI50 |
5.3 μM
Compound: 48
|
Growth inhibition of human SKBR3 cells after 5 days by SRB assay
Growth inhibition of human SKBR3 cells after 5 days by SRB assay
|
[PMID: 25723005] |
| SW-620 | GI50 |
0.38 μM
Compound: 48
|
Growth inhibition of human SW620 cells after 5 days by SRB assay
Growth inhibition of human SW620 cells after 5 days by SRB assay
|
[PMID: 25723005] |
In Vitro
CFI-400945 (compound 48) shows potent inhibitory activities against a panel of kinases, including PLK4, TRKA, TRKB, AURKA, AURKB/INCENP, and TIE2/TEK, with IC50s of 2.8, 6, 9, 140, 98, 22 nM, and EC50s of 12, 84, 88, 510, 102, 117 nM, respectively. CFI-400945 exhibits growth inhibition effects on breast, lung, ovarian and colon cancer cells. The IC50s (in μM) are as follows: SKBr-3 (5.3), Cal-51 (0.26), BT-20 (0.058), A549 (0.005), OVCAR-3 (0.018), SW620 (0.38), Colo-205 (0.017), and HCT116+/+ (0.004) [1]. CFI-400945 inhibits autophosphorylation of PLK4 at serine 305 with an EC50 value of 12.3 nM in cells overexpressing PLK4. Cancer cells treated with CFI-400945 exhibit effects consistent with PLK4 kinase inhibition, including dysregulated centriole duplication, mitotic defects, and cell death[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1338806-73-7
-
Appearance Solid
-
분자량 534.65
-
화학식 C33H34N4O3
-
Color White to yellow
-
SMILES
O=C([C@@]12[C@H](C3=CC4=C(C=C3)C(/C=C/C5=CC=C(CN6C[C@@H](C)O[C@@H](C)C6)C=C5)=NN4)C1)NC7=C2C=C(OC)C=C7
-
Synonyms
CFI-400945 free base
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Nanotechnol
Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. [Abstract]2021 Jul;16(7):830-839. PMID: 33958764 -
Cell Death Differ
GSDME acts as an epigenetic modifier to promote melanoma development via centriole biogenesis regulator PLK4. [Abstract]2026 May 25. PMID: 42185629 -
J Integr Plant Biol
2026 Apr 2. PMID: 41928062 -
-
Int J Mol Med
MicroRNA‑126 suppresses the proliferation and migration of endothelial cells in experimental diabetic retinopathy by targeting polo‑like kinase 4. [Abstract]2021 Jan;47(1):151-160. PMID: 33416109 -
Ocifisertib purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2026 Jun 18.
MCF7 and MCF7-TP53-KO cells were treated with ocifisertib (25 nM), PPM1Di (250 nM) or combination of both for 5 days and cleavage of caspase 7 was assayed by immunoblotting.
-
-
J Cancer Res Clin Oncol
Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells. [Abstract]2020 Nov;146(11):2871-2883. PMID: 32770382
Ocifisertib purchased from MedChemExpress. Usage Cited in: J Cancer Res Clin Oncol. 2020 Nov;146(11):2871-2883. [Abstract]
Treatment with CFI-400945 and centrinone induced the appearance of the 89 kDa PARP1 cleavage product in a concentration-dependent manner.
Ocifisertib purchased from MedChemExpress. Usage Cited in: J Cancer Res Clin Oncol. 2020 Nov;146(11):2871-2883. [Abstract]
PLK4i induces DNA damage in WE-68 cells. Cells were exposed to CFI-400945 or centrinone for 2 hours. Phosphorylation levels of H2AX were detected by immunoblotting.
-
Ir J Med Sci
PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling. [Abstract]2023 Apr;192(2):561-567. PMID: 35508865
Ocifisertib purchased from MedChemExpress. Usage Cited in: Ir J Med Sci. 2023 Apr;192(2):561-567. [Abstract]
Representative images showing the expression of PLK4, p-PI3K, PI3K, p-AKT, AKT, and GAPDH in RPMI-8226 cells treated with CFI-400945 (200 nM), bortezomib, 740 YP, or a combination thereof, as detected by Western blotting.
Ocifisertib purchased from MedChemExpress. Usage Cited in: Ir J Med Sci. 2023 Apr;192(2):561-567. [Abstract]
Effects of bortezomib, CFI-400945 (200 nM), or their combination on the relative survival rate and TUNEL-positive rate (200× magnification) of RPMI-8226 cells.
용액&용해도
In Vitro:
DMSO : 100 mg/mL (187.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.68 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (285 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sampson PB, et al. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5?'-methoxyspiro[cyclopropane-1,3?'-indolin]-2?'-one (CFI-400945) as a potent, orally active antitumor agent. J Med Chem. 2015 Jan 8;58(1):147-69. [Content Brief]
[2]. Mason JM, et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26(2):163-76. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8704 mL | 9.3519 mL | 18.7038 mL | 46.7596 mL |
| 5 mM | 0.3741 mL | 1.8704 mL | 3.7408 mL | 9.3519 mL | |
| 10 mM | 0.1870 mL | 0.9352 mL | 1.8704 mL | 4.6760 mL | |
| 15 mM | 0.1247 mL | 0.6235 mL | 1.2469 mL | 3.1173 mL | |
| 20 mM | 0.0935 mL | 0.4676 mL | 0.9352 mL | 2.3380 mL | |
| 25 mM | 0.0748 mL | 0.3741 mL | 0.7482 mL | 1.8704 mL | |
| 30 mM | 0.0623 mL | 0.3117 mL | 0.6235 mL | 1.5587 mL | |
| 40 mM | 0.0468 mL | 0.2338 mL | 0.4676 mL | 1.1690 mL | |
| 50 mM | 0.0374 mL | 0.1870 mL | 0.3741 mL | 0.9352 mL | |
| 60 mM | 0.0312 mL | 0.1559 mL | 0.3117 mL | 0.7793 mL | |
| 80 mM | 0.0234 mL | 0.1169 mL | 0.2338 mL | 0.5845 mL | |
| 100 mM | 0.0187 mL | 0.0935 mL | 0.1870 mL | 0.4676 mL |
Ocifisertib Related Classifications
HY-12300 Related Classifications
Powered by Bioz